Impact of Ambulatory Continuous Monitoring Using Remote Monitoring Medicine Within Patient's Care Pathway Following Colorectal Surgery (CONTACT-GRECCAR 21)

NCT ID: NCT06850688

Last Updated: 2025-12-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

362 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-06-17

Study Completion Date

2026-10-17

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this Clinical Investigation is to evaluate the effectiveness of implementing the discharge protocol of the remote monitoring platform after colorectal surgery in patients at risk of hospital readmission.

Participants will be randomized into either the "30 days of remote monitoring" group or the "conventional discharge" group. The patient returns to the site for their postoperative visit at 30 days and is contacted by phone 90 days after their surgery.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colorectal Surgery Readmission

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

conventional discharge

The patients will be discharged from the hospital through standard discharge procedures. They will be seen on Day 30 during their routine postoperative consultation and then contacted by phone on Day 90. All patients will be required to complete a patient diary from Day 0 to the telephone contact on Day 90 in order to record their healthcare utilization during this period.

Group Type NO_INTERVENTION

No interventions assigned to this group

Remote monitoring plateform

Patient monitoring via the remote monitoring platform for 30 days after hospital discharge. They will be seen on Day 30 during their routine postoperative consultation and then contacted by phone on Day 90. All patients will be required to complete a patient diary from Day 0 to the telephone contact on Day 90 in order to record their healthcare utilization during this period.

The qualitative component includes data collection through semi-structured individual interviews with a sample of patients, as well as data collection through focus groups with a sample of healthcare professionals involved in the system.

Group Type EXPERIMENTAL

Remote monitoring platform

Intervention Type DEVICE

EPOCA Intelligence Information System is a remote monitoring plateform. The medical device is used as a SaaS platform with restricted access for healthcare professionals. Patients and their families interact with the medical device via notifications and secure links, upon request. The medical device integrates the use of other medical devices such as oximeters, blood pressure monitors, glucometers, bracelets, etc., which are connected and whose use is also governed by their user manuals and training.

Patient is monitoring via the remote monitoring platform for 30 days after hospital discharge

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Remote monitoring platform

EPOCA Intelligence Information System is a remote monitoring plateform. The medical device is used as a SaaS platform with restricted access for healthcare professionals. Patients and their families interact with the medical device via notifications and secure links, upon request. The medical device integrates the use of other medical devices such as oximeters, blood pressure monitors, glucometers, bracelets, etc., which are connected and whose use is also governed by their user manuals and training.

Patient is monitoring via the remote monitoring platform for 30 days after hospital discharge

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Man or woman over 18 years old at the time of the J0 visit,
* Patient who has undergone colorectal surgery not managed on an outpatient basis at the investigator center,
* At least one of the following two criteria:
* Anticipated early discharge (within 24 hours following laparoscopic surgery without diversion and within 5 days following surgery by laparotomy with stoma) for a surgery not managed on an outpatient basis in routine practice,
* Estimated risk of hospital readmission greater than 10% according to the nomogram of Tevis et al. \[15\], adapted to the postoperative context in digestive surgery (\>120 points according to this score).
* Patient affiliated with a health insurance plan,
* Patient who has signed the study consent form.

Exclusion Criteria

* Discharge to a rehabilitation center requested by the patient,
* Condition managed on an outpatient basis in routine practice for this type of patient,
* Patient eligible for home hospitalization services,
* Suicidal or hetero-aggressive risk in a patient living alone at home
* Homeless patient,
* Pregnant or breastfeeding women,
* Patient under legal guardianship, curatorship, or protected legal status,
* Patient already enrolled in an interventional postoperative follow-up study.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

EPOCA U&I

INDUSTRY

Sponsor Role collaborator

Ministry of Health, France

OTHER_GOV

Sponsor Role collaborator

Nantes University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHRU Tours

Tours, , France

Site Status RECRUITING

CHU Angers

Angers, , France

Site Status RECRUITING

Clinique Tivoli- Ducos

Bordeaux, , France

Site Status RECRUITING

CHU Grenoble

Grenoble, , France

Site Status RECRUITING

Centre Hospitalier Lyon-Sud

Lyon, , France

Site Status RECRUITING

CHU Timone - Assistance publique-Hôpitaux de Marseille

Marseille, , France

Site Status RECRUITING

Hôpital Nord - Assistance publique- Hôpitaux de Marseille

Marseille, , France

Site Status RECRUITING

Institut Paoli Calmettes

Marseille, , France

Site Status NOT_YET_RECRUITING

CHU Nantes

Nantes, , France

Site Status RECRUITING

Hôpital de Bicêtre - Assistance Publique Hôpitaux de Paris

Paris, , France

Site Status RECRUITING

Hôpital Saint Antoine - Assistance publique - Hôpitaux de Paris

Paris, , France

Site Status RECRUITING

CHU Rennes

Rennes, , France

Site Status RECRUITING

Clinique Mutualiste de l'estuaire

Saint-Nazaire, , France

Site Status RECRUITING

CHU Toulouse

Toulouse, , France

Site Status NOT_YET_RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Emilie DUCHALAIS

Role: CONTACT

+33 2 40 08 43 22

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Aurélien VENARA

Role: primary

+33 2 41 35 36 18

Quentin DENOST

Role: primary

33 5 47 50 15 75

Bertrand TRILLING

Role: primary

+33 4 76 76 93 77

Eddy COTTE

Role: primary

33 4 78 86 23 71

Diane MEGE

Role: primary

+33 4 91 38 57 99

Laura BEYER- BERJOT

Role: primary

+33 4 91 96 50 90

Hélène MEILLAT

Role: primary

+33 4 91 22 36 60

Emilie DUCHALAIS

Role: primary

+33 2 40 08 43 22

Solafah ABDALLA

Role: primary

+33 1 45 21 34 70

Jérémie LEFEVRE

Role: primary

+33 1 71 97 04 19

Véronique DESFOURNEAUX DENIS

Role: primary

+33 2 99 28 91 36

Maxime GERARD

Role: primary

+33 2 72 27 53 82

Etienne BUSCAIL

Role: primary

33 5 61 32 23 73

Mehdi OUAISSI

Role: primary

+33 2 18 37 05 75

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2024-A01770-47

Identifier Type: REGISTRY

Identifier Source: secondary_id

RC22_0452

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

CPET in Colorectal Surgery
NCT02298907 COMPLETED
Safe Anastomosis Feasibility Study
NCT05180565 COMPLETED NA